Giredestrant

Published

dm+d

Unassigned

New Medicines

Metastatic ER-positive HER2-negative breast cancer - second or third-line monotherapy

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Next generation selective estrogen receptor degrader/down regulator (SERD) that fully blocks ER signalling with robust receptor occupancy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone tx)
There are around 55,200 new breast cancer cases in the UK every year. About 80% of all breast cancers are ER-positive [2].
Metastatic ER-positive HER2-negative breast cancer - second or third-line monotherapy
Oral